Group 1 - Daikin Heavy Industries' subsidiary signed a contract worth approximately 1.339 billion yuan for an offshore wind farm project in Europe, accounting for 35.41% of the company's audited revenue for 2024 [1] Group 2 - Zhaoyi Innovation announced that several board members and senior management plan to reduce their holdings by a total of 249,000 shares, due to personal financial needs, with the reduction period set from December 15, 2025, to March 14, 2026 [2] Group 3 - Jushi Chemical received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws, while the company's operations continue normally [3][6] Group 4 - Chaozhuo Aerospace announced a stock suspension due to major matters being planned by its controlling shareholders, which may lead to a change in control [4] Group 5 - Heng Rui Medicine received approval for clinical trials of SHR-1139 injection, a biopharmaceutical with no similar products approved for sale domestically or internationally, with a cumulative R&D investment of approximately 100.13 million yuan [5] Group 6 - Huayou Pharmaceutical's HYP-6589 tablet for treating advanced non-small cell lung cancer received a clinical trial application acceptance notice, with no similar products approved for sale [8] Group 7 - Renfu Pharmaceutical's application for the marketing license of Dexamethasone L-amphetamine capsules was accepted, aimed at treating ADHD, with a cumulative R&D investment of approximately 90 million yuan [10] Group 8 - Huibo Group won a bid for a 1.596 billion yuan project for the restoration of an oil field in Iraq [10]

Core Viewpoint - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the drug registration approval notice from the National Medical Products Administration for the marketing of Dexamethasone Mesylate Capsules [2] Company Summary - The company holds an 80% stake in Yichang Renfu Pharmaceutical Co., Ltd. [2] - The approval is a significant step for the company in expanding its product offerings in the pharmaceutical market [2] Industry Summary - The approval from the National Medical Products Administration indicates a positive regulatory environment for pharmaceutical companies in China [2] - The introduction of new drugs like Dexamethasone Mesylate Capsules may enhance competition and innovation within the industry [2]

Regulatory Actions - Haosai is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, but the company states that its operations remain normal and the investigation will not significantly impact management [2] - Central Plaza and its executives received a warning letter from the Jiangsu Securities Regulatory Bureau for failing to timely disclose significant litigation progress, which led to inaccurate financial reporting [3] - Guolian Aquatic received a warning letter from the Guangdong Securities Regulatory Bureau for non-operating fund occupation by its controlling shareholder, which was not disclosed in a timely manner [9] Corporate Actions - Jiarong Technology is planning a major asset restructuring and has suspended trading of its shares, expected to last no more than 10 trading days [4] - Maiwei Co. announced a debt restructuring totaling 371 million yuan, with an expected loss of 85.465 million yuan, aimed at improving cash flow and reducing receivables risk [5] - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, with a total of 575 million yuan already invested in such products [6] Legal Matters - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 7.4073 million yuan [8] Product Development - Huyou Pharmaceutical's HYP-6589 tablet has received acceptance for clinical trial applications for treating advanced non-small cell lung cancer [7] - Renfu Pharmaceutical's application for the marketing license of a new ADHD treatment has been accepted, with no similar products currently available in the domestic market [10] Strategic Partnerships - Jindi Co. signed a strategic cooperation letter of intent with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies and key components [11] Share Buybacks and Holdings - Yuyuan Co. has repurchased 1 million A-shares for a total of approximately 5.3864 million yuan as part of a buyback plan [12] - Yuheng Pharmaceutical's executives increased their holdings by 1.12%, acquiring a total of 25 million shares [13] Major Contracts - Huayou Huibo has been awarded a contract worth 225 million USD for the Iraq NaftKhana oilfield project, which is expected to significantly impact future earnings [16] - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, representing 35.41% of the company's expected annual revenue [17]

Core Viewpoint - The company has received acceptance for the drug registration application of Dexamfetamine Mesylate Capsules, which is currently not available in the domestic market, indicating a potential expansion of its product line and market competitiveness [1] Group 1: Company Developments - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the drug registration application [1] - The drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 and above [1] - The total R&D investment in this project amounts to approximately 90 million RMB [1] Group 2: Market Implications - The acceptance of the drug registration application marks the entry of the product into the review phase, which, if successfully approved, will enhance the company's product offerings [1] - Currently, there are no similar products approved for sale or import in the domestic market, indicating a unique market opportunity for the company [1]

Core Viewpoint - The approval of the drug registration application for Dextroamphetamine Sulfate Capsules by the National Medical Products Administration marks a significant step for the company, indicating the product is entering the review phase, which could enhance the company's product line and market competitiveness [1] Group 1 - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Dextroamphetamine Sulfate Capsules from the National Medical Products Administration [1] - Currently, there are no Dextroamphetamine Sulfate Capsules available in the domestic market, nor have any related products been approved for import [1] - The total R&D investment by Yichang Renfu in this project has reached approximately 90 million RMB [1]

Core Insights - The company announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Dexmethylphenidate Hydrochloride Capsules from the National Medical Products Administration [1] - This drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 and above [1] - Currently, there are no similar products available in the domestic market or approved for import, indicating a potential market opportunity for the company [1] Financial and R&D Investment - The cumulative R&D investment for this project by Yichang Renfu is approximately 90 million RMB [1] - The acceptance of the drug registration application marks the entry of this product into the review phase, which, if successfully approved, will enhance the company's product line and market competitiveness [1]

证券代码：600079 证券简称：人福医药 编号：临 2025-122 人福医药集团股份公司 关于子公司药品上市许可申请获受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 人福医药集团股份公司（以下简称"公司"）控股子公司宜昌人福药业有限责 任公司（以下简称"宜昌人福"，公司持有其80%的股权）近日收到国家药品监督管 理局核准签发的二甲磺酸利右苯丙胺胶囊的药品注册上市许可申请《受理通知书》， 现将相关情况公告如下： 一、药物名称：二甲磺酸利右苯丙胺胶囊 二、剂型：胶囊剂 三、申请事项：境内生产药品注册上市许可 四、注册分类：化学药品3类 五、申请人：宜昌人福药业有限责任公司 六、审查结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。受理号：CYHS2504001、CYHS2504003、CYHS2504004、 CYHS2504006。 二甲磺酸利右苯丙胺胶囊原研最早于美国获批上市，用于治疗成人和 6 岁及以 上儿科患者的注意缺陷多动障碍（ADHD），以及成人中度至重度暴食症（B ...

据悉，二甲磺酸利右苯丙胺胶囊原研最早于美国获批上市，用于治疗成人和6岁及以上儿科患者的注意 缺陷多动障碍(ADHD)，以及成人中度至重度暴食症(BED)。宜昌人福本次提交本品的上市许可申请申 报的适应症为成人和6岁及以上儿科患者的注意缺陷多动障碍(ADHD)。根据国家药品监督管理局官网 显示，国内目前暂无二甲磺酸利右苯丙胺胶囊上市，也无相关产品获批进口。截至目前，宜昌人福在该 项目上的累计研发投入约9,000万元人民币。 智通财经APP讯，人福医药(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(以下简 称"宜昌人福"，公司持有其80%的股权)近日收到国家药品监督管理局核准签发的二甲磺酸利右苯丙胺 胶囊的药品注册上市许可申请《受理通知书》。 ...

格隆汇11月21日丨人福医药（维权）(600079.SH)公布，控股子公司宜昌人福药业有限责任公司（简 称"宜昌人福"，公司持有其80%的股权）近日收到国家药品监督管理局核准签发的二甲磺酸利右苯丙胺 胶囊的药品注册上市许可申请《受理通知书》，二甲磺酸利右苯丙胺胶囊原研最早于美国获批上市，用 于治疗成人和6岁及以上儿科患者的注意缺陷多动障碍（ADHD），以及成人中度至重度暴食症 （BED）。 ...

每经AI快讯，11月21日，人福医药(600079.SH)公告称，控股子公司宜昌人福近日收到国家药品监督管 理局核准签发的二甲磺酸利右苯丙胺胶囊的药品注册上市许可申请《受理通知书》。该药物用于治疗成 人和6岁及以儿科患者的注意缺陷多动障碍（ADHD）。目前国内暂无该药品上市，也无相关产品获批 进口。宜昌人福在该项目上的累计研发投入约9000万元人民币。药品注册上市许可申请被受理，标志着 该品种境内生产药品注册工作进入了审评阶段，如顺利通过审评审批，将丰富公司的产品线，有利于提 升公司的市场竞争力。 （文章来源：每日经济新闻） ...